Analysis on the Pathogenesis of Symptomatic Pulmonary Embolism with Human Genomics

Hao Wang¹*, Qianglin Duan¹*, Lemin Wang¹**, Zhu Gong¹, Aibin Liang², Qiang Wang¹, Haoming Song¹, Fan Yang³, Yanli Song⁴

1. Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China;
2. Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China;
3. Department of Laboratory Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China;
4. Department of Emergency, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.

* Contributed equally.

Abstract

BACKGROUND: In the present study, the whole human genome oligo microarray was employed to investigate the gene expression profile in symptomatic pulmonary embolism (PE).

METHODS: Twenty patients with PE and 20 age and gender matched patients without PE as controls were enrolled into the present study in the same period. The diagnosis of PE was based on the clinical manifestations and findings on imaging examinations. Acute arterial and/or venous thrombosis was excluded in controls. The whole human genome oligo microarray was employed for detection. Statistical analysis was performed with t test following analysis of very small samples of repeated measurements and Gene Ontology (GO) analysis.

RESULTS: Genomic data showed no damage to vascular endothelial cells in PE patients. Genomic data only found increased mRNA expression of a small amount of coagulation factors in PE patients. In the PE group, anticoagulant proteins, Fibrinolytic system and proteins related to platelet functions only played partial roles in the pathogenesis of PE. In addition, the mRNA expressions of a fraction of adhesion molecules were markedly up-regulated. Gene Ontology analysis showed the genes with down-regulated expressions mainly explain the compromised T cell immunity. Symptomatic VTE patients have compromised T cell immunity.

CONCLUSION: The damage to vascular endothelial cells is not necessary in the pathogenesis of VTE, and only a fraction of factors involved in the shared coagulation cascade are activated. Genomic results may provide a new clue for clinical diagnosis, treatment and prevention of VTE.

Key words: Human genomics; Pulmonary embolism (PE); T cell immunity; Adhesion molecules

Introduction

Thrombus which may result in pulmonary embolism (PE) mostly comes from deep venous thrombosis (DVT). Altogether, both PE and DVT are named venous thromboembolism (VTE). Because of the high incidence of misdiagnosis, morbidity and mortality, VTE has become one of the essential medical problems around world (1, 2). After 1990’s, clinical report of incidence of PE are sharply increased yearly in China (3). After 1990’s, clinical reports of PE are sharply increased yearly in China (3). In other Asia
regions, such as Japan, Thailand, Singapore, Taiwan, the number of reported PE cases is also increasing (4-8). There are nearly 900,000 new PE cases in USA every year (9), 78,000 new cases in Canada, 100,000-200,000 cases in Europe including France, Italy, Spain, Britain, Germany, and 47,000 cases in Australia every year (10). According to the statistical data, provided by an epidemiological surveillance in US, PE is the third leading cause of death (11, 12), only lags behind malignancy and myocardial infarction.

Virchow’s classical triad of abnormalities including blood stasis, hypercoagulability and vessel damage has been regarded as the authentic theory for explaining pathogenesis of VTE since 19’s century (13), however, the triad does not fit all clinical profiles.

In 1965, Egeberg et al (14) firstly introduced the concept of thrombophilia based on discovering a family with an autosomal dominant inheritance disease whose members manifested with repeatedly onset of DVT due to depletion of antithrombin III. Since then, many reports have considered that genetic gene mutation was one of the major factors in the pathogenesis of VTE (15), but there has been a lack of sufficient genetic etiology evidence in many clinical PE patients.

In recent years, some scholars have suggested that DVT-PE is a heterogeneous polygenic and multifactor disease involving the interaction of hereditary factors and environment with many risk factors such as trauma, surgery, advanced age, malignancy, pregnancy, heart failure, stasis, oral contraceptive, and so on (16). In 2004 and 2008, ACCP proposed risk stratifications in patients receiving surgery, and different strategies should be performed for patients with different risks to prevent the occurrence of VTE (17,18). However, the annual number of VTE cases is increasing over year actually. Generally, the traditional concept can merely be verified merely in few patients with VTE, the pathogenesis of majority of other patients is still to be elucidated.

Gene chip analysis provides the advanced tool for the study of gene function (19-21). It can be a reliable approach for the study of differential gene expression between healthy people and patients and for the elucidation of molecular etiology of VTE.

Materials and methods

Patient information

Twenty patients enrolled in PE group were those who admitted in hospital during 2007, with 11 males and 9 females, averaged 70(±14) years of age(44-89 years old). ALL patients were diagnosed as PE in accordance with at least 2 of following criteria. 1)Selective pulmonary arteriography showed filling defect or blockage; 2) Pulmonary ventilation perfusion scanning exhibited single or multiple blood flow perfusion defect with normal or abnormal ventilation, mismatched ratio of ventilation/perfusion; 3) Other clinical characteristics including typical manifestation of PE, arterial blood gas analysis, D-dimer test, ultrasoundcardiogram (UCG) and chest computerized tomography (CT) supported the diagnosis and excluded other cardiac and pulmonary disorders. Twenty patients with ischemic heart disease admitted at same period, excluding PE, DVT and other congenital bleeding and thrombosis diseases with comparative clinical presentation (11 males, 9 females, 44-91 years old with mean age 72±14) were enrolled in control group. The study protocol was approved by local ethics committee and informed consent was obtained from all patients in accordance with the declaration of Helsinki.

Total RNA isolation

5 ml of peripheral blood samples anti-coagulated with EDTA were drawn from patients suspected with PE immediately after admitting to the hospital and from those patients without PE, respectively. Mononuclear cells were obtained through density gradient centrifugation with Ficoll solution and remaining red blood cells were destroyed with erythrocyte lysis buffer (Qiagen, Hilden, Germany). Total mononuclear cell RNA was extracted with TRIzol(Invitrogen, Carlsbad, USA) and purified with Qiagen RNeasy column (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Isolated total RNA was testified and quantified by means of Nanodrop ND-1000 spectrophotometer (Nanodrop Technology, Cambrige, UK).

Targets preparation and microarrays hybridization

RNA samples of patients with confirmed diagnosis of PE and controls were labeled using indirect labeling method. Briefly, 1µg of total RNA was reverse transcribed. The cDNA then undergoes second strand synthesis and clean-up to become a template for in vitro transcription (IVT) with T7 RNA Polymerase. During IVT, the modified nucleotide, 5-(3-aminonallyl)-UTP (aaUTP) was incorporate into the cDNA. After that, fluorescent Cy3 was chemically coupled to aaUTP which contains a reactive primary amino group on the C5 position of uracil. The dye incorporation rate was assessed with a Nanodrop ND-1000 spectrophotometer and was found to be between 1.2 and 1.4 pmol/µl. Hybridization was carried out using the Agilent oligonucleotide microarray in situ hybridization plus kit (p/n 5184-3568), fol-
lowing the manufacturer’s instructions. Briefly, 750 ng of Cy3 labeled sample cDNA was subjected to frag-
mentation (30 min at 60°C) and then hybridization on 44K Human Whole-Genome 60-mer oligo-chips (G4112F, Agilent Technologies) in a rotary oven (10 rpm, 60°C, 17 h). Slides were disassembled and washed in solutions I and II according to the manufacturer’s instructions.

**Statistical analysis**

**Significant differential gene expression analysis**

Random variance model (RVM) corrected t-test was used for the differential gene expression screen-
ing due to the small number of patients (20 cases each group) was far less than the amount of genes and low freedom degree of gene expression signal. P<0.05 is criterion of significantly different genes.

**Go analysis**

Gene Ontology organizes gene function into hi-
erarchical categories based on biological process, mo-
lecular function and cellular component (22-24). Fisher’s exact test was applied for over representation of selected genes in GO biological categories. In order to assess the significance of a particular category by random chance, false discovery rate (FDR) was esti-
ated for all of categories. After 5,000 re-samplings, FDR was defined as FDR=1-Nr/T, where Nr refers to the subtracted number which was from Fisher’s test p-values minus x² test p-values in random samples. We specified the threshold of significant GO as p-value<0.05, FDR<0.05 and enrichment parameters. Enrichment represents the degree of gene expression significance. The equation of enrichment is as fol-
lowing

\[ R_s = \frac{(n_s/n)}{(N_s/N)} \]

where ns is the number of significant genes within the particular category, n is the total number of genes within the same category, Ns is the number of significant genes in the entire microarray, N is the number of all genes tested.

Similar to GO analysis, Fisher’s exact test was employed for the study of over-representation of se-
lected genes.

**Results**

**Significantly differential gene expressions of VTE formation related factors associated with traditional theory**

According to the traditional theory, the patho-
genesis of VTE is associated with abnormalities in blood flow, vessel integrity and blood components. Therefore, we compared gene expressions of these VTE related factors in patients with PE and without PE. Among the expressions of coagulation factor genes, only gene expressions of factor IIand FIBCD1 were significantly elevated in patients with PE compared with patients without PE. As for genes of other coagulant factors, the expression value of patients with PE was either not significantly different or less than those patients without PE in comparison. There was no significant difference between two groups of patients in gene expression of anticoagulant proteins. And so was in gene expression of fibrinolytic factors except plasminogen Urokinase receptor (PLAUR, Fig.1). L-selectin, ITGAL and ICAM-1 are the adhe-
sion molecules originated from different family, mainly distributed on the surface of lymphocytes. ICAM-1 is the ligand of ITGAL which is member of integrin family. Significantly elevated mRNA expres-
sion of these adhesion molecules in PE group indicate activated adhesion function of white blood cells. However, mRNA expression of P-selectin (mainly distributed on the surface of ECs and platelets) and E-selection (mainly distributed on the surface of activated ECs) are not elevated in PE group which indi-
cate venous endothelial cells are not impaired in pa-
tients with PE (Fig.2). In expression of platelet aggre-
gation related genes, only 2 genes (GP6 and PAFAH1B2) were significantly elevated in the pa-
tients with PE. Compared to patients without PE, the expressions of 3 in 7 genes of platelet adhesion func-
tion were significantly increased in patients with PE. As for genes of platelet releasing, the expression of one gene was significantly up and down regulated between 2 groups of patients, respectively (Fig.3).

**Function distribution of significantly differential genes by Gene Ontology analysis**

To identify the gene categories with differential expression in patients with or without PE, Gene On-
tology analysis was carried out on the experiment data. The union of all differential expression genes resulted from data analysis are 2308 genes in patients with PE compared to patients without PE. Among them, 2238 genes are up-regulated and 70 are down-regulated. The main gene ontology categories impacted by these genes involve the up-regulation of 19 functioning categories against 4 down-regulation categories. Up-regulated genes are those genes whose functions are associated with transformation, phos-
phorylation, cell survival and cell conjugation, et al. While the function of down-regulated genes are rele-
ant to the function of plasma membrane and activity of receptors, especially to the lymphocyte receptor complex and immunological synapse (Fig.4).
Fig. 1 A, There was no significant difference in comparison of gene mRNA expression of coagulant factors between 2 groups. Compared to patients without PE, mRNA expression of 2 (FIBCD1) and F7 among 15 genes are significantly elevated in patients with PE. B, There are no significantly differences in mRNA expression of anticoagulant factors between 2 patient groups, which suggests these anticoagulant factors did not play roles in the VTE pathogenesis. C, Compared to control group, only 1 (PLAUR) of 7 gene mRNA expression of fibrinolysis factors is significantly different.

Fig. 2 Significantly elevated mRNA expression of L-selectin, ITGAL and ICAM-1 were detected in PE group than control. However, mRNA expression of P-selectin (mainly distributed on the surface of ECs and platelets) and E-selection (mainly distributed on the surface of activated ECs) are not elevated in PE group.
Fig. 3 A, B and C demonstrate the differential mRNA expression of platelet functioning genes in PE and control group. Compared to patients without PE, significantly elevated mRNA expression were found only in 2 (GP6, PAFAH1B2) of 11 genes of aggregation, 3 (GP1BA, GP9 and ITGA2B) of 7 genes of adhesion and 1 (THBS3) of 15 genes of releasing, respectively.

Fig. 4 Gene ontology analysis exhibited compromised T cell mediated immune function, and t test indicated associated genes were significantly down-regulated in patients with PE than in control groups.
**Discussion**

Two genes with down-regulated expressions are closely related to the T cell mediated immunity according to GO analysis (with high value of enrichment). These results reveal that T cell mediated immunity has been declined markedly in PE patients. The declined T cell receptor complex displayed as significantly diminished mRNA expression of CD3G, CD3D, CD247, ZAP-70, T cell granzyme A and B, which will result in loss of functions of cytotoxic T cells.

Additionally, the high mRNA expression of L-selectin, ITGAL and ICAM-1 in PE patients revealed the elevated adhesion of vascular endothelial cells, white blood cells and platelets which indicated that the adhesion molecules play an important role in the pathogenesis of VTE.

The functions of platelets are characterized by aggregation, adhesion and release response (25). Our results showed the mRNA expressions of 3/7 adhesion molecules were markedly up-regulated in PE patients, which suggests the adhesion of platelets plays an important role in the pathogenesis of PE.

In 2011, we reported the proportions of CD3+ T cells and CD8+ T cells were markedly reduced and CD4/CD8 significantly increased in a series of CTEPH patients, which suggests the compromised T cell immunity in CTEPH patients and imbalance between CD3+ T cells and CD8+ T cells (26). In addition, we also found that the number of CD3+ T cells and CD8+ T cells was dramatically reduced in a series of acute PE patients and cytological findings also supported the results from genomics studies on PE patients (27). The occurrence of PE is related to the deficient or compromised T cell mediated immunity. This deficiency of T cell immunity may occur under the following conditions: 1) viral infection; 2) malignant tumors; 3) medication with immunosuppressants; 4) malnutrition. In the present study, most of subjects were old patients and malnutrition was not clinically obvious. Moreover, malignant tumors were not found in these patients and medication with immunosuppressants was absent. Thus, the compromised T cell immunity might be possibly related to viral infection.

In 2010, we reported a patient who died of SARS developed VTE in multiple organs, which implies the viral infection induced systemic VTE and there is correlation between viral infection and occurrence of VTE (28).

Comparisons between PE patients and controls revealed the mRNA expressions of only a few proteins in the coagulation system, anti-coagulation system and fibrinolysis system were markedly up-regulated and only 3 factors or receptors in the shared coagulation cascade were activated, which was inconsistent with traditional theory that coagulation factors are comprehensively activated.

We reported in our previous study that the main component of thrombus in acute venous thrombosis was fibrinogen and albumin and cytoskeletal proteins accounted for only a minor fraction of the thrombus (29). The thrombus composed of fibrinogen is unstable, which makes the delayed thrombolysis feasible and also explain the therapeutic effectiveness of transcatheter thrombolysis not long after APE. Findings support that the formation of thrombus in VTE is not due to the comprehensive activation of coagulation factors as in traditional theory.

In the present study, we apply the unitarian theory to explain the pathogenesis of symptomatic VTE: the occurrence of symptomatic VTE is closely related to the compromised immune function as well as the viral infection. This also explains why VTE is frequently found in patients with advanced age, trauma, surgery, malignant tumors, heart failure, immobilization, pregnancy and other risk factors. Our findings provide new knowledge on the etiology and pathophysiology of VTE and novel clue for the clinical diagnosis, treatment and prevention of VTE.

**Acknowledgment**

This study was supported by “12th five year” National Science and Technology Supporting Program (2011BAI11B16).

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

[1] Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006;25:101-61.

[2] Spencer FA, Gore JM, Lessard D, Douketis JD, Emery C, Goldberg RJ. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med 2008;168:425-30.

[3] He J, Cheng X, Gao M. [Survey of diagnosis and treatment of acute pulmonary embolism in 21 hospitals in China]. Zhonghua Yi Xue Za Zhi 2001;81:1490-2.

[4] Sakuma M, Konno Y, Shirato K. Increasing mortality from pulmonary embolism in 21 hospitals in China]. Zhonghua Yi Xue Za Zhi 2001;81:1490-2.

[5] Palwatwichai A, Gaewtam-Manugul P, Aplratpracha W, Vattanathum A, Tantamacharik D, Wongsa A. Clinical and laboratory findings in patients with pulmonary embolism in Phramongkutklao Hospital. J Med Assoc Thai 2000;83:1463-70.

[6] Lee L H. Clinical update on deep vein thrombosis in Singapore. Ann Acad Med Singapore 2002;31:248-52.

[7] Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost 2005;3:2664-70.
[8] Leizorovicz A. Epidemiology of post-operative venous thromboembolism in Asian patients. Results of the SMART venography study. Haematologica 2007;92:1194-200.
[9] Rankob GE, Silverstein R, Bratztler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010;38(4 Suppl):S502-9.
[10] [Internet] Pulmonary Embolism. http://www.wrongdiagnosis.com/p/pulmonary_embolism/stats-country.htm
[11] Flyers, TM. Venous thromboembolism. Am J Respir Crit Care Med 1999; 99: 1-14.
[12] Tierney LM, McPhee SJ, Papadakis MA. Disorders of pulmonary circulation: pulmonary thromboembolism. Current Medical Diagnosis and Treatment 2000; 39: 321-30.
[13] Virchow R. Gesammelte abhandlungen zur wissenschaftlichen medizin. Frankfurt, Medinger: Sohn & Company. 1856.
[14] Egeberg O. Inherited Antithrombin Deficiency Causing Thrombophilia. Thromb Diath Haemorrh 1965;13:516-30.
[15] Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001;109:369-84.
[16] Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:453S-535S.
[17] Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010;38(4 Suppl):S502-9.
[18] Hyers, TM. Venous thromboembolism. Am J Respir Crit Care Med 1999; 99: 1-14.
[19] Tierney LM, McPhee SJ, Papadakis MA. Disorders of pulmonary circulation: pulmonary thromboembolism. Current Medical Diagnosis and Treatment 2000; 39: 321-30.
[20] Virchow R. Gesammelte abhandlungen zur wissenschaftlichen medizin. Frankfurt, Medinger: Sohn & Company. 1856.
[21] Egeberg O. Inherited Antithrombin Deficiency Causing Thrombophilia. Thromb Diath Haemorrh 1965;13:516-30.
[22] Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001;109:369-84.
[23] Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S.
[24] Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010;38(4 Suppl):S502-9.
[25] Fliers, TM. Venous thromboembolism. Am J Respir Crit Care Med 1999; 99: 1-14.
[26] Tierney LM, McPhee SJ, Papadakis MA. Disorders of pulmonary circulation: pulmonary thromboembolism. Current Medical Diagnosis and Treatment 2000; 39: 321-30.
[27] Virchow R. Gesammelte abhandlungen zur wissenschaftlichen medizin. Frankfurt, Medinger: Sohn & Company. 1856.
[28] Egeberg O. Inherited Antithrombin Deficiency Causing Thrombophilia. Thromb Diath Haemorrh 1965;13:516-30.
[29] Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001;109:369-84.
[30] Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:453S-535S.
[31] Brown PO, Botstein D. Exploring the new world of the genome with gene microarrays. Nat Genet 1999;21:33-7.